As of 2025-01-18, the Relative Valuation of Enanta Pharmaceuticals Inc (ENTA) is (121.71) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.85 USD, the upside of Enanta Pharmaceuticals Inc based on Relative Valuation is -2609.5%.
The range of the Relative Valuation is (101.20) - (120.26) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.1x - 22.0x | 17.6x |
| Forward P/E multiples | 18.5x - 35.7x | 26.8x |
| Fair Price | (101.20) - (120.26) | (121.71) |
| Upside | -2186.7% - -2579.6% | -2609.5% |
| Date | P/E |
| 2025-01-07 | -0.98 |
| 2025-01-06 | -1.02 |
| 2025-01-03 | -1.02 |
| 2025-01-02 | -1.02 |
| 2024-12-31 | -1.05 |
| 2024-12-30 | -1.07 |
| 2024-12-27 | -1.10 |
| 2024-12-26 | -1.10 |
| 2024-12-24 | -1.11 |
| 2024-12-23 | -1.16 |
| 2024-12-20 | -1.15 |
| 2024-12-19 | -1.07 |
| 2024-12-18 | -1.07 |
| 2024-12-17 | -1.12 |
| 2024-12-16 | -1.15 |
| 2024-12-13 | -1.10 |
| 2024-12-12 | -1.15 |
| 2024-12-11 | -1.28 |
| 2024-12-10 | -1.58 |
| 2024-12-09 | -1.63 |
| 2024-12-06 | -1.46 |
| 2024-12-05 | -1.46 |
| 2024-12-04 | -1.56 |
| 2024-12-03 | -1.60 |
| 2024-12-02 | -1.56 |
| 2024-11-29 | -1.57 |
| 2024-11-27 | -1.61 |
| 2024-11-26 | -1.56 |
| 2024-11-25 | -1.65 |
| 2024-11-22 | -1.71 |
| 2024-11-21 | -1.70 |
| 2024-11-20 | -1.66 |
| 2024-11-19 | -1.72 |
| 2024-11-18 | -1.75 |
| 2024-11-15 | -1.74 |
| 2024-11-14 | -1.85 |
| 2024-11-13 | -1.90 |
| 2024-11-12 | -1.95 |
| 2024-11-11 | -1.98 |
| 2024-11-08 | -2.02 |
| 2024-11-07 | -2.07 |
| 2024-11-06 | -2.10 |
| 2024-11-05 | -2.06 |
| 2024-11-04 | -2.03 |
| 2024-11-01 | -2.00 |
| 2024-10-31 | -2.05 |
| 2024-10-30 | -2.10 |
| 2024-10-29 | -2.10 |
| 2024-10-28 | -2.11 |
| 2024-10-25 | -2.13 |